-
Posted by
Two Blokes Apr 28 -
Filed in
Stock
-
4 views
Nearly everything looked great with AbbVie's (ABBV 3.10%) first-quarter results. The big drugmaker's revenue jumped 8.4% year over year, thanks largely to spectacular growth from autoimmune disease drugs Skyrizi and Rinvoq.